
    
      The primary objective of phase 1 is to evaluate the safety of CART regimens. The primary
      objective of phase 2 is to evaluate the efficacy of CART, as measured by objective response
      rate in subjects with colorectal cancer. Secondary objectives will include assessing the
      safety and tolerability of CART and additional efficacy endpoints.
    
  